A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF OP-1250 MONOTHERAPY VS STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2- ADVANCED OR METASTATIC BREAST CANCER FOLLOWING ENDOCRINE AND CDK 4/6 INHIBITOR THERAPY (OPERA-01)
- Registry ID
- OP-1250-301
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- OLEMA PHARMACEUTICALS, INC.
- Start date
- 2024-08-30
- Last update
- 2023-11-23
Conditions
- BREAST CANCER
- BREAST CANCER, HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC
Related clinical trials
- AN OPEN-LABEL, MULTI-CENTER, PHASE I/IB STUDY OF IEV407 AS A SINGLE AGENT AND IN COMBINATION WITH ENDOCRINE THERAPY IN PATIENTS WITH ADVANCED HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE BREAST CANCER
- 68Ga FAPI PET/CT Evaluation of Axillary Lymph Node Status After Neoadjuvant Therapy in Patients With Clinical Axillary Lymph Node Positive Breast Cancer
- Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients
- A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS RIBOCICLIB PLUS FULVESTRANT VERSUS PLACEBO PLUS RIBOCICLIB PLUS FULVESTRANT IN PATIENTS WITH ENDOCRINE-RESISTANT HORMONE-RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH CHROMOSOME 8P LOSS AND WITHOUT A PIK3CA MUTATION
- A PHASE IB/II MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY
EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF
GDC-4198 ALONE AND IN COMBINATION WITH GIREDESTRANT IN
COMPARISON WITH ABEMACICLIB AND GIREDESTRANT IN
PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC
ESTROGEN RECEPTOR-POSITIVE, HER2 NEGATIVE BREAST CANCER
WHO HAVE PREVIOUSLY PROGRESSED DURING OR AFTER A CDK4/6
INHIBITOR
- A PHASE 3 OPEN-LABEL RANDOMIZED STUDY ASSESSING THE EFFICACY AND
SAFETY OF RLY-2608 + FULVESTRANT VERSUS CAPIVASERTIB + FULVESTRANT AS TREATMENT FOR
PIK3CA-MUTANT HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR
2 NEGATIVE (HR+/HER2-) LOCALLY ADVANCED OR METASTATIC BREAST CANCER FOLLOWING RECURRENCE OR PROGRESSION ON OR AFTER TREATMENT WITH A CDK4/6 INHIBITOR
View on source registry